Lindenwold Advisors INC Makes New Investment in Zoetis Inc. $ZTS

Lindenwold Advisors INC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, HoldingsChannel reports. The institutional investor bought 16,736 shares of the company’s stock, valued at approximately $2,449,000. Zoetis accounts for approximately 1.2% of Lindenwold Advisors INC’s portfolio, making the stock its 22nd largest position.

Several other hedge funds have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC grew its position in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares in the last quarter. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the third quarter valued at about $31,000. Financial Consulate Inc. bought a new stake in shares of Zoetis in the third quarter valued at about $39,000. SJS Investment Consulting Inc. lifted its stake in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after acquiring an additional 257 shares during the period. Finally, TruNorth Capital Management LLC purchased a new stake in Zoetis in the third quarter worth about $42,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS opened at $117.42 on Thursday. The firm has a market capitalization of $49.57 billion, a PE ratio of 19.50, a price-to-earnings-growth ratio of 1.86 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business’s 50-day moving average is $124.80 and its two-hundred day moving average is $130.99. Zoetis Inc. has a 1 year low of $114.47 and a 1 year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm posted $1.40 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Ratings Changes

ZTS has been the topic of a number of research reports. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. KeyCorp started coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Finally, William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.